la AEHH bets for the training of young specialists and awarded five scholarships aimed at research.
-the Spanish society of Haematology and haemotherapy (AEHH) awards through its Foundation grants to projects of basic research, to advance in the knowledge of the meaning of the alterations and to identify factors of prognostic value
-At the Congress the AEHH LIII, recently held in Zaragoza, five new research fellowships were awarded
-the latest ratings emphasize the need to know the genetic and molecular alterations in order to better establish the prognosis and treatment of Myelodysplastic syndromes
Madrid, November 2011- La Sociedad Española de HematologÃa Hemoterapia (AEHH), has among its purposes the scientific advancement in relation to the study and treatment of diseases caused by alterations in blood components. Why, it awards grants to projects of basic research, to advance in the knowledge of the meaning of the alterations and to identify factors of prognostic value through his Foundation.
At the Congress the AEHH LIII, recently held in Zaragoza, were awarded five new fellowships for research. proposed items relate primarily to hematologic cancers with poor prognosis and are aimed at studying genetic or molecular ”, points out Dr. Carmen Burgaleta, President of the AEHH. With the award of these fellowships aim to stimulate interest in research among the younger specialists ”, add the hematóloga.
The main reason for study scholarships are the myelodysplastic syndromes (MDS). This pathology includes a complex group of hemopathies stemmed from the bone marrow, which is characterized by an alteration in the maturation of the elements of the blood, who studied with Cytopenias of varying intensity that can evolve into acute leukemia or maintain a chronic course.
The SMD appear approximately 7 of every 100,000 inhabitants and have higher incidence in people over 60 years, since its presence increases progressively with age. According to Dr. Burgaleta, latest ratings emphasize the need to know the alterations genetic and molecular in order to better establish his prognosis and adapt accordingly, treatment ”. The availability of new therapeutic agents to modify its evolution has revolutionized research in these processes.
The scholarships have been granted to the following research projects:
– is the study of the genetic changes of patients with myelodysplastic syndrome 5q-treated with lenalidomide ”.
– The search for patterns of response in relation to the study of Hematopoiesis by flow cytometry in affected patients of myelodysplastic syndrome of high-risk treatment with 5-Azacitidine ”
– study of trisomy 8 in patients with myelodysplastic syndrome and/or Behçet syndrome ”.
The projects will be carried out in the service of Hematology of the Hospital del Mar, in Barcelona, and in the service of Hematology and Salamanca cancer research centre.
Likewise, the foundation of the AEHH has awarded several scholarships to leukaemia research projects:
– study of the frequency and significance prognosis of deletions/mutations of the gene IKZF1 and the State of hypermethylation of genes hsa-miR-375, HDPR1 (DACT1), SHP1 (PTPN6), P16 (CDKN2A), hsa-miR-9-3 and DBC1 in adult patients with acute lymphoblastic leukemia without reordering BCR-ABL1 included in treatment protocols adapted to the risk of the Group PETHEMA (programme Spanish of therapies in hematology.)”, of the Hospital Germans Trias i Pujol, Badalona (Barcelona).
-Project about disease Graft versus host in transplanted patients: study of the usefulness of the Zalypsis in disease prevention Graft versus host after allogeneic hematopoietic precursors transplant ”, from Hospital ClÃnico Universitario de Salamanca.
On the Spanish society of Haematology and haemotherapy (AEHH)
The AEHH is a scientific society whose purpose is the promotion, development and dissemination of integrity and content of the speciality of Haematology and haemotherapy in its aspects medical, scientific, organizational, health care, teaching and research. Likewise, arises the need to approach to society in generalin such a way that be perceived and properly understand the value of the professional role of the hematologist and its competence in medicine. Its central axis consists of 17 cooperative groups that currently are, each focused on a specific aspect of the specialty. With 53 years of life, the AEHH is today a powerful organization with a considerable scientific impact, since many of the more than 2,000 professional Hematologists as part of her are internationally recognized figures for many years thus becoming one of the most visible parts of Spanish medicine abroad.
